Effect of Immunosuppressive Drugs on the Changes of Serum Galactose-Deficient IgA1 in Patients with IgA Nephropathy
Min Jeong Kim(Kantonsspital Aarau), Jonathan Barratt(University of Leicester)
Cited by 33
Related Papers
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
|The Lancet|2023|264
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
|The Lancet|2023|214
Artificial intelligence and machine learning in nephropathology
|Kidney International|2020|107
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
|Kidney International Reports|2023|59